ClinicalTrials.gg
RecruitingNCT06189391Updated Oct 29, 2026

A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)

A Phase 1 interventional study of MK-1045 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, sponsored by MSD R&D (China) Co., Ltd.. Recruiting at 15 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by MSD R&D (China) Co., Ltd. (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Mar 2021, registered Aug 2023).
  • Started Mar 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Researchers are looking for new ways to treat people with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). B-cells are a type of white blood cells that make antibodies and help fight infections. Non-Hodgkin Lymphoma is a type of cancer in the lymphatic system causing enlarged lymph nodes and/or organs in belly or chest. Relapsed means a disease or condition comes back after treatment Refractory means a disease does not respond to treatment or stops responding to a treatment.

MK-1045, the study medicine, is designed to treat relapsed or refractory B-NHL. MK-1045 is an immunotherapy, which is a treatment that helps the immune system fight cancer.

This is the first study in which MK-1045 will be given to people. The goal of this study is to learn about:

  • The safety of MK-1045 and how well people tolerate it.
  • The highest dose of MK-1045 that is well tolerated.
  • How well MK-1045 works to treat relapsed or refractory B-NHL.
02

Conditions studied

  • Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Browse trials for

03

In context

Lead sponsor

MSD R&D (China) Co., Ltd. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion/Exclusion Criteria:

Inclusion Criteria

Inclusion Criteria include, but are not limited to:

  • Has B-cell Non-Hodgkin's lymphoma (B-NHL) with disease history meeting the following World Health Organization (WHO) diagnostic subtypes of B-NHL that are CD19-positive in pathologic immunohistochemistry test: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) (Grade I to III), marginal zone lymphoma, lymphoplasmacytic lymphoma, mantle cell lymphoma, small lymphocytic lymphoma, and transformed large B-cell lymphoma (During the dose-escalation phase, participants, excluding those treated with Chimeric antigen receptor T-cell (CAR-T) who cannot provide proof of pathologic immunohistochemistry CD19 positivity but have previous proof of CD20 positivity may be considered for enrollment after communication with the sponsor)

    • Relapse is defined as the occurrence of progressive disease (PD) after complete response (CR) or partial response (PR) has been achieved after adequate treatment. Note: For DLBCL participants, relapse must occur after participants undergoing at least two ; for other participants, they must undergo at least one line of therapy.
    • Refractory is defined as a situation that there is no standard of care available or that it is not applicable to use standard of care at this stage, including: Participants who are unresponsive to standard of care (e.g., monotherapy or combination therapy containing anti-CD20 monoclonal antibody) and whose best response to standard therapy is PD or stable disease (SD); Participants who are not eligible for hematopoietic stem cell transplantation (ASCT) and have relapsed PD after receiving ASCT; Participants who have failed on chimeric antigen receptor T cell (CAR-T) immunotherapy, but the first dose of the study intervention must be at least 3 months after discontinuation of CAR-T therapy, and CD19 positive expression is still present in tumor tissue.
  • Has at least one evaluable tumor lesion per the Lugano 2014 criteria, i.e., a lymph node lesion > 15 mm in long diameter or an extranodal lesion > 10 mm in long diameter according to computed tomography (CT) cross-sectional imaging or magnetic resonance imaging (MRI)
  • Has an (ECOG) performance score of ≤ 2 and an estimated survival time of more than 3 months
  • Has essentially normal: bone marrow function; coagulation function; liver function; kidney function; lung function; and heart function

Exclusion Criteria

Exclusion Criteria include, but are not limited to:

  • Has any other non-Hodgkin lymphoma (NHL) not listed in inclusion criteria
  • Has been treated with anti-CD3/CD19 bispecific antibody (BsAb) prior to first dose of study intervention
  • Has received chemotherapy, endocrine therapy, radiotherapy (palliative radiotherapy 2 weeks prior to the first administration of the drug), or biologic therapy, and small molecule targeted agents within 2 weeks prior to the first administration of the investigational drug or within 5 half-lives of the drug, whichever is shorter
  • Has received anti-CD20 antibody or anti-CD19 antibody within 4 weeks prior to first use of the investigational drug
  • Has received anti-tumor immunotherapy or other unlisted clinical study intervention within 4 weeks prior to the first dose of study intervention, or within 5 half-lives of the drug, whichever is shorter
  • Has undergone any major organ surgery (excluding aspiration ) or significant trauma within 4 weeks prior to the first dose of study intervention or those requiring elective surgeries during the study
  • Has received systemic (prednisone >10 mg/day or equivalent) or other agents within 14 days prior to the first dose of the study intervention, excluding the following agents: topical, ocular, intra-articular, intranasal, and inhaled corticosteroids, and short-term, prophylactic use of corticosteroids (e.g. to prevent radio contrast agent induced allergic reactions)
  • Has used immunomodulatory agents, including but not limited to thymosin, interleukin-2 (IL-2), interferon (IFN) and anti-tumor Chinese patent drugs or Chinese herbal medicines within 14 days prior to the first dose of study intervention
  • Has had a within 4 weeks prior to the first dose of study intervention
  • Has a central nervous system (CNS) infiltration
  • Has previous or concomitant CNS diseases, including epilepsy, severe brain injury, dementia, Parkinson's disease, cerebellar disorder, organic cerebellar syndrome, or mental diseases
  • Has prior or concomitant (except cured basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, prostatic intraepithelial neoplasia, and other tumors that have been clinically cured for 5 years as assessed by the investigator)
  • Has uncontrolled active infections currently requiring systemic anti-infective therapy within 3 days prior to first dose
  • Has active and/or . Participants who are positive for antibodies to hepatitis C virus (HCV). Participants who are hepatitis B surface antigen (HBsAg) positive are not allowed to enroll in the dose-escalation period; however, those who were hepatitis B surface antigen (HBsAg)-positive but hepatitis B Virus deoxyribonucleic acid (HBV DNA)-negative and adherent to entecavir antiviral therapy and who agreed to regular monthly monitoring of HBV DNA are allowed to enroll in the dose-expansion period
  • Has a history of immunodeficiency, including testing positive for (HIV) antibody
  • Has a history of serious cardiovascular and cerebrovascular disease, including but not limited to: severe cardiac rhythm or conduction abnormalities; acute coronary syndrome, congestive heart failure, stroke, or other Grade 3 or higher cardiovascular and cerebrovascular events within 6 months prior to the first dose; ≥ Class II cardiac function as per (NYHA) functional class or \< 50%; or clinically uncontrollable hypertension
  • Has previous or current interstitial lung disease
  • Has acute (GVHD) or active chronic GVHD at present
  • Has active or history of diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, vasculitis, psoriasis, etc.) that may relapse, or participants who are at risks (e.g., organ transplant requiring immunosuppressive therapy). Participants with the following diseases are allowed to be further screened for enrollment: hypothyroidism managed with hormone replacement therapy only, and skin diseases not requiring systemic treatment (such as vitiligo, psoriasis, or alopecia).
  • Has received immunotherapy with known Grade 3 or higher immune-related adverse events (irAEs)
  • Has non-hematologic adverse reactions from prior anti-tumor therapy have not recovered to Grade ≤ 1 as assessed by National Cancer Institute NCI (NCI-CTCAE) Version 5.0 (excluding toxicities such as alopecia that are assessed by the investigator to have no safety risk)
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    MK-1045 Fixed Dose

    Participants will receive MK-1045 via intravenous (IV) infusion on Day 1 of each week for 3 consecutive weeks followed by one week off of each four-week cycle for up to 12 months until discontinuation or death.

    Drug: MK-1045

  • Experimental
    MK-1045 Step-up Dose

    Participants will receive MK-1045 via an IV infusion in a step-up dose with priming once a week (Q1W) for a 3-week cycle for up to 12 months until discontinuation or death.

    Drug: MK-1045

Interventions

  • IV infusion

    Also known as: CN201

06

What researchers measure

Primary outcomes

  1. Number of Participants who Experience a Dose-limiting Toxicity (DLT)

    DLT are any of the following drug related (DR) investigator-assessed adverse events: Grade 4 neutropenia that does not recover to Grade ≤ 2 after more than 5 days of supportive care including granulocyte colony-stimulating factor (G-CSF), or ≥ Grade 3 febrile neutropenia; Grade 4 platelet (PLT) decreased, or Grade 3 PLT decreased with bleeding; Grade 4 anemia. Grade 4 non-hematologic toxicity; Grade 3 non-hematologic toxicity that does not recover to Grade ≤ 2 within 3 days after best supportive care (excluding simple laboratory abnormalities without clinical significance as assessed by the investigator). Participants with ≥ Grade 3 tumor lysis syndrome who recover to ≤ Grade 2 within 14 days after optimal supportive therapy will be excluded from the definition of DLT. A DLT was also any other toxic reactions requiring permanent discontinuation of the study intervention.

    Time frame: Up to ~28 Days

  2. Number of Participants who Experience an Adverse Event (AE)

    An AE is defined as any untoward medical event that occurs after a participant receives the investigational drug, which may be manifested as symptoms, signs, diseases, or laboratory abnormalities, but may not necessarily have a causal relationship with the study intervention. The number of participants who experience an AE will be reported.

    Time frame: Up to ~15 months

  3. Number of Participants who Experience a Serious Adverse Events (SAE)

    An SAE refers to an untoward medical occurrence such as death, life-threatening event, permanent or serious disability or loss of function, need for hospitalization or prolongation of hospitalization after the participant receives the intervention, and congenital abnormalities or birth defects. The number of participants who experience a SAE will be reported.

    Time frame: Up to ~15 months

  4. Number of Participants who Experience a Drug-related Adverse Event (DRAE)

    An AE is defined as any untoward medical event that occurs after a participant receives the investigational drug, which may be manifested as symptoms, signs, diseases, or laboratory abnormalities, but may not necessarily have a causal relationship with the study intervention. A DRAE is defined as an AE definitely related, probably related, or possibly related to the study intervention. The number of participants who have experienced a DRAE will be reported.

    Time frame: Up to ~15 months

  5. Number of Participants who Experience an AE of Grade 3 or higher

    An AE is defined as any untoward medical event that occurs after a participant receives the study intervention, which may be manifested as symptoms, signs, diseases, or laboratory abnormalities, but may not necessarily have a causal relationship with the study intervention. AEs are graded on a scale from 1-5 with 1=Mild, 2=Moderate, 3=Severe or medically significant but not immediately life-threatening, 4= Life threatening consequences, and 5=Death due to AE. The number of participants who experience an AE of grade 3 or above will be presented.

    Time frame: Up to ~15 months

  6. Number of Participants who Experience an AE for Each Severity Grade from 1-5

    An AE is defined as any untoward medical event that occurs after a participant receives the study intervention, which may be manifested as symptoms, signs, diseases, or laboratory abnormalities, but may not necessarily have a causal relationship with the study intervention. AEs are graded on a scale from 1-5 with 1=Mild, 2=Moderate, 3=Severe or medically significant but not immediately life-threatening, 4= Life threatening consequences, and 5=Death due to AE. The number of participants who experience an AE in each category of AEs from 1-5 will be presented.

    Time frame: Up to ~15 months

  7. Number of Participants who Experience a SAE or Serious Drug-related AE

    An SAE refers to an untoward medical occurrence such as death, life-threatening event, permanent or serious disability or loss of function, need for hospitalization or prolongation of hospitalization after the participant receives the study intervention, and congenital abnormalities or birth defects. A drug related SAE is defined as an SAE definitely related, probably related, or possibly related to the study intervention. The number of participants who experience a SAE or a serious drug-related AE will be reported.

    Time frame: Up to ~15 months

  8. Number of Participants who Experience a Dose Modification Due to an AE or DRAE

    An AE is defined as any untoward medical event that occurs after a participant receives the study intervention, which may be manifested as symptoms, signs, diseases, or laboratory abnormalities, but may not necessarily have a causal relationship with the study intervention. A drug related AE includes AEs definitely related, probably related, and possibly related to the study intervention. The number of participants who experience a dose modification due to an AE or DRAE will be presented.

    Time frame: Up to ~15 months

  9. Number of Participants who Withdraw from the Study due to an AE or DRAE

    An AE is defined as any untoward medical event that occurs after a participant receives the study intervention, which may be manifested as symptoms, signs, diseases, or laboratory abnormalities, but may not necessarily have a causal relationship with the study intervention. A drug related AE includes AEs definitely related, probably related, and possibly related to the study intervention. The number of participants who discontinue the study due to an AE will be presented.

    Time frame: Up to ~15 months

  10. Number of Participants who Died due to an AE or DRAE

    An AE is defined as any untoward medical event that occurs after a participant receives the study intervention, which may be manifested as symptoms, signs, diseases, or laboratory abnormalities, but may not necessarily have a causal relationship with the study intervention. A drug related AE includes AEs definitely related, probably related, and possibly related to the study intervention. The number of participants who died due to an AE or DRAE will be presented.

    Time frame: Up to ~15 months

Secondary outcomes

  1. Mean Change in Serum MK-1045 Concentration After Administration

    Blood samples will be collected to determine the mean change from baseline in serum concentration of MK-1045.

    Time frame: Baseline and up to 12 months

  2. Area Under the Concentration-time Curve (AUC) of MK-1045

    Blood samples will be collected to determine the AUC of MK-1045 in plasma.

    Time frame: Pre-dose and at designated time points post-dose up to 12 months

  3. Area Under the Concentration-time Curve from Time 0 to 168 Hours Post Dose (AUC0-168) of MK-1045

    Blood samples will be collected to determine the AUC0-168 of MK-1045 in plasma.

    Time frame: Pre-dose and at designated time points post-dose up to 168 hours

  4. Area Under the Concentration-time Curve from Time 0 to Last Quantifiable Concentration Post Dose (AUC0-last) of MK-1045

    Blood samples will be collected to determine the AUC0-last of MK-1045 in plasma.

    Time frame: Pre-dose and at designated time points post-dose up to 168 hours

  5. Maximum Concentration (Cmax) of MK-1045

    Blood samples will be collected to determine the Cmax of MK-1045 in plasma.

    Time frame: Pre-dose and at designated time points post-dose up to 12 months

  6. Time to Maximum Concentration (Tmax) of MK-1045

    Blood samples will be collected to determine the Tmax of MK-1045 in plasma.

    Time frame: Pre-dose and at designated time points post-dose up to 12 months

  7. Terminal Elimination Half-life (T1/2) of MK-1045

    Blood samples will be collected to determine the t1/2 of MK-1045 in plasma.

    Time frame: Pre-dose and at designated time points post-dose up to 12 months

  8. Clearance (CL) of MK-1045

    Blood samples will be collected to determine the CL of MK-1045 in plasma.

    Time frame: Pre-dose and at designated time points post-dose up to 12 months

  9. Concentration at the End of Dosing Interval (Ctrough) of MK-1045

    Blood samples will be collected to determine the Ctrough of MK-1045 in plasma.

    Time frame: Pre-dose and at designated time points post-dose up to 12 months

  10. Area Under the Concentration-time Curve from Time 0 to the Dosing Interval (168 Hours) at Steady State (AUC0-tau) of MK-1045

    Blood samples will be collected to determine the AUC0-tau of MK-1045 in plasma.

    Time frame: Pre-dose and at designated time points post-dose up to 168 hours

  11. Accumulatio Ratio Based on Cmax (RAC-Cmax) of MK-1045

    Blood samples will be collected to determine the RAC\_Cmax of MK-1045 in plasma.

    Time frame: Pre-dose and at designated time points post-dose up to 12 months

  12. Accumulation Ratio Based on AUC0-tau (RAC_AUC0-tau) of MK-1045

    Blood samples will be collected to determine the RAC-AUC0-tau of MK-1045 in plasma.

    Time frame: Pre-dose and at designated time points post-dose up to 12 months

  13. Steady State Clearance (CLss) of MK-1045

    Blood samples will be collected to determine the CLss of MK-1045 in plasma.

    Time frame: Pre-dose and at designated time points post-dose up to 12 months

  14. Steady State Apparent Volume of Distribution (Vss) of MK-1045

    Blood samples will be collected to determine the Vss of MK-1045.

    Time frame: Pre-dose and at designated time points post-dose up to 12 months

  15. Mean Number of B Cells in Peripheral Blood After Administration of MK-1045

    Blood samples will be collected to determine the mean number of B cells in peripheral blood after treatment with MK-1045.

    Time frame: Baseline and up to 12 months

  16. Mean Number of T cells in Peripheral Blood After Administration of MK-1045

    Blood samples will be collected to determine the mean number of T cells in peripheral blood after treatment with MK-1045.

    Time frame: Baseline and up to 12 months

  17. Mean Level of T Cell Activation After Administration with MK-1045

    Blood samples will be collected to determine the mean T cell activation after treatment with MK-1045.

    Time frame: Baseline and up to 12 months

  18. Mean Level of T Cell Proliferation After Administration of MK-1045

    Blood samples will be collected to determine the mean level of T cell proliferation after treatment with MK-1045.

    Time frame: Baseline and up to 12 months

  19. Mean Level of Cytokines in Peripheral Blood After Administration of MK-1045

    Blood samples will be collected to determine the mean level of cytokines after treatment with MK-1045.

    Time frame: Baseline up to 12 months

  20. Percentage of Participants who Develop Anti-drug Antibodies (ADA) to MK-1045

    Blood samples will be collected to determine the percentage of participants with ADAs to MK-1045 after treatment with MK-1045.

    Time frame: Baseline and up to 15 months

  21. Objective Response Rate (ORR)

    ORR is defined as the percentage of the participants who had complete response (CR) or partial response (PR) and will be evaluated using computed tomography (CT) and positron emission tomography (PET)-CT. Response will be assessed based on the International Working Group Criteria: Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014). CR is complete metabolic (no/minimal fluorodeoxyglucose \[FDG\] uptake) and radiologic response (target lesions regress to ≤5 cm in longest transverse diameter of a lesion) and no new lesions. PR is partial metabolic (moderate/high FDG uptake) and radiologic response (≥50% decrease in sum of product diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \>50% in length beyond normal). The percentage of participants who experience CR or PR will be presented.

    Time frame: Up to 15 months

  22. Duration of Response (DOR)

    For participants who demonstrate a CR or PR, DOR is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first. Participants will be evaluated using CT and metabolic imaging (FDG-PET). CR is complete metabolic (no/minimal FDG uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. PR is partial metabolic (moderate/high FDG uptake) and radiologic response (≥50% decrease in sum of product diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \>50% in length beyond normal). DOR will be presented among participants who demonstrated CR or PR.

    Time frame: Up to ~15 months

  23. Complete Response Rate (CRR)

    CRR is defined as the percentage of the participants who had complete response (CR) and will be evaluated using computed tomography (CT) and positron emission tomography (PET)-CT. Response will be assessed based on the International Working Group Criteria: Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014). CR is complete metabolic (no/minimal fluorodeoxyglucose \[FDG\] uptake) and radiologic response (target lesions regress to ≤5 cm in longest transverse diameter of a lesion) and no new lesions. The percentage of participants who experience a CR will be presented.

    Time frame: Up to ~15 months

  24. Duration of Complete Response (DCR)

    For participants who demonstrate a CR, DCR is defined as the time from the first documented evidence of CR until disease progression or death due to any cause, whichever occurs first. Participants will be evaluated using CT and metabolic imaging (FDG-PET). CR is complete metabolic (no/minimal FDG uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. DCR for participants with CR will be presented.

    Time frame: Up to ~15 months

  25. Progression Free Survival (PFS)

    PFS is defined as the time from first dose to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. PD per Lugano criteria is defined as new or increased adenopathy, splenic volume increase, new or larger non-measured lesions, recurrent previously resolved lesions, new extranodal lesion \>1 cm in any axis, a new node \>1.5 cm in any axis. PFS will be presented.

    Time frame: Up to ~15 months

07

Study locations

13 of 15 sites recruiting
  • Fifth Medical Center of PLA General Hospital ( Site 0005)
    Beijing, Beijing Municipality 100071, China
    Recruiting
    • Study Coordinator · Contact+861066947114
  • Beijing Cancer hospital ( Site 0001)
    Beijing, Beijing Municipality 100142, China
    Recruiting
    • Study Coordinator · Contact01088196116
  • The First Affiliated Hospital of Xiamen University ( Site 0011)
    Xiameng, Fujian 361000, China
    Recruiting
    • Study Coordinator · Contact0592 2139866
  • Sun Yat-Sen University Cancer Center ( Site 0003)
    Guangzhou, Guangdong 510060, China
    Recruiting
    • Study Coordinator · Contact020 87343349
  • The Fourth Hospital of Hebei Medical University. ( Site 0004)
    Shijiazhuang, Hebei 050035, China
    Recruiting
    • Study Coordinator · Contact031186296322
  • Henan Cancer Hospital ( Site 0009)
    Zhengzhou, Henan 450000, China
    Recruiting
    • Study Coordinator · Contact400-0371-818
  • The First Affiliated Hospital of Zhengzhou University ( Site 0006)
    Zhengzhou, Henan 451161, China
    Recruiting
    • Study Coordinator · Contact0371-67966266
  • Jiangxi Cancer Hospital ( Site 0007)
    Nanchang, Jiangxi 330029, China
    Recruiting
    • Study Coordinator · Contact079188317256
  • The First Hospital Of Jilin University ( Site 0014)
    Changchun, Jilin 130021, China
    Recruiting
    • Study Coordinator · Contact8613039046656
  • Shandong Cancer Hospital ( Site 0008)
    Jinan, Shandong 250117, China
    Active, not recruiting

    Not enrolling at this site.

  • Fudan University Shanghai Cancer Center ( Site 0012)
    Shanghai, Shanghai Municipality 200030, China
    Recruiting
    • Study Coordinator · Contact+86216417559082107
  • Zhongshan Hospital,Fudan University ( Site 0013)
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
    • Study Coordinator · Contact021-64041990-692225
  • Shanghai East Hospital ( Site 0002)
    Shanghai, Shanghai Municipality 200120, China
    Recruiting
    • Study Coordinator · Contact02138804518
  • Sichuan Cancer Hospital. ( Site 0018)
    Chengdu, Sichuan 610041, China
    Recruiting
    • Study Coordinator · Contact028-85420305
  • Tianjin Medical University Cancer Institute and Hospital ( Site 0010)
    Tianjinc, Tianjin Municipality 300060, China
    Active, not recruiting

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2021 (actual). Primary completion is estimated for Sep 2028, 90 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2023
First posted
Jan 3, 2024
StartActual
Mar 16, 2021
Primary completionEst.
Sep 30, 2028
CompletionEst.
Mar 30, 2029
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06189391
Responsible party
Sponsor
First posted
Jan 3, 2024
Start date
Mar 16, 2021
Primary completion
Sep 30, 2028 (estimated)
Completion
Mar 30, 2029 (estimated)
Last update
Oct 29, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp and Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD19/CD3 Bispecific Antibody MK-1045

Start the discussion